Thomas Shrader
Stock Analyst at BTIG
(3.61)
# 2,878
Out of 5,182 analysts
95
Total ratings
47.78%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTHI NeOnc Technologies Holdings | Initiates: Buy | $15 | $4.31 | +248.03% | 1 | Apr 24, 2026 | |
| CMPS COMPASS Pathways | Reiterates: Buy | $14 | $8.44 | +65.88% | 2 | Apr 20, 2026 | |
| HROW Harrow | Reiterates: Buy | $63 | $40.48 | +55.63% | 5 | Apr 17, 2026 | |
| DRUG Bright Minds Biosciences | Reiterates: Buy | $147 | $88.99 | +65.19% | 5 | Mar 30, 2026 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Buy | $8 | $2.46 | +225.20% | 5 | Mar 26, 2026 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $4 | $2.70 | +48.15% | 4 | Mar 26, 2026 | |
| DNLI Denali Therapeutics | Maintains: Buy | $36 → $38 | $20.06 | +89.43% | 6 | Mar 25, 2026 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $2.95 | +747.46% | 4 | Mar 24, 2026 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $33.33 | +17.01% | 3 | Mar 19, 2026 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $3.03 | +164.03% | 4 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 | $2.39 | +151.05% | 5 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $12 | $5.00 | +140.00% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.38 | +624.64% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $89 | $58.73 | +51.54% | 7 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $28 | $24.47 | +14.43% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $7.92 | +139.90% | 1 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $9.61 | +66.49% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $4.26 | +275.59% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.57 | +473.25% | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $8.87 | +159.30% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.85 | +386.49% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.40 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $10.85 | +1,743.32% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $7.10 | +745.07% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $6.00 | +16.67% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,400 → $650 | $4.30 | +15,016.28% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.21 | +4,114.88% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.56 | +250.88% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.77 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.51 | +98.68% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $183.38 | +88.68% | 3 | Feb 21, 2019 |
NeOnc Technologies Holdings
Apr 24, 2026
Initiates: Buy
Price Target: $15
Current: $4.31
Upside: +248.03%
COMPASS Pathways
Apr 20, 2026
Reiterates: Buy
Price Target: $14
Current: $8.44
Upside: +65.88%
Harrow
Apr 17, 2026
Reiterates: Buy
Price Target: $63
Current: $40.48
Upside: +55.63%
Bright Minds Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $147
Current: $88.99
Upside: +65.19%
Acumen Pharmaceuticals
Mar 26, 2026
Reiterates: Buy
Price Target: $8
Current: $2.46
Upside: +225.20%
Ovid Therapeutics
Mar 26, 2026
Reiterates: Buy
Price Target: $4
Current: $2.70
Upside: +48.15%
Denali Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $20.06
Upside: +89.43%
NRx Pharmaceuticals
Mar 24, 2026
Reiterates: Buy
Price Target: $25
Current: $2.95
Upside: +747.46%
Stoke Therapeutics
Mar 19, 2026
Reiterates: Buy
Price Target: $39
Current: $33.33
Upside: +17.01%
AC Immune
Mar 16, 2026
Reiterates: Buy
Price Target: $8
Current: $3.03
Upside: +164.03%
Mar 10, 2026
Upgrades: Buy
Price Target: $6
Current: $2.39
Upside: +151.05%
Mar 2, 2026
Maintains: Buy
Price Target: $7 → $12
Current: $5.00
Upside: +140.00%
Feb 26, 2026
Reiterates: Buy
Price Target: $10
Current: $1.38
Upside: +624.64%
Feb 26, 2026
Maintains: Buy
Price Target: $85 → $89
Current: $58.73
Upside: +51.54%
Feb 17, 2026
Maintains: Buy
Price Target: $27 → $28
Current: $24.47
Upside: +14.43%
Jan 20, 2026
Reiterates: Buy
Price Target: $19
Current: $7.92
Upside: +139.90%
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $9.61
Upside: +66.49%
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $4.26
Upside: +275.59%
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $1.57
Upside: +473.25%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $8.87
Upside: +159.30%
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $1.85
Upside: +386.49%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.40
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $10.85
Upside: +1,743.32%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $7.10
Upside: +745.07%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $6.00
Upside: +16.67%
Mar 28, 2023
Maintains: Buy
Price Target: $3,400 → $650
Current: $4.30
Upside: +15,016.28%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.21
Upside: +4,114.88%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $4.56
Upside: +250.88%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.77
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.51
Upside: +98.68%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $183.38
Upside: +88.68%